-
Je něco špatně v tomto záznamu ?
Evaluation of the therapeutic effects of combined hydroxychloroquine and azithromycine in patients with covid-19
Zeina A. Althanoon
Jazyk angličtina Země Česko
- MeSH
- azithromycin farmakologie terapeutické užití MeSH
- COVID-19 * MeSH
- farmakoterapie COVID-19 MeSH
- hydroxychlorochin farmakologie terapeutické užití MeSH
- kombinovaná farmakoterapie MeSH
- lidé MeSH
- Check Tag
- lidé MeSH
Introduction: Coronavirus pandemic is currently a global health concern with no established treatment guidelines. The aim of the present study was to determine the therapeutic effectiveness of hydroxychloroquine combined with azithromycin in patients with positive coronavirus disease 2019 (COVID-19) admitted to the hospital with severe dyspnea, as well as the incidence of occurrence of adverse effects.Methods: It was intended to utilize a retrospective clinical study of approximately 250 adult patients admitted to the ALSALAM Teaching Hospital in Mosul city with mild to moderate COVID-19 in order to evaluate treatment efficacy in combination with clinical and biochemical findings. Two groups were involved in the research. The first patient group consisted of 250 people who got hydroxychloroquine in conjunction with azithromycin, while the second untreated control group consisted of 100 individuals who received no medication as part of the research.Results: Baseline parameters (clinical and biochemical assays) did not vary substantially among the two groups. Patients in the treatment group were hospitalized at a rate of 30%, compared to 27% in the untreated control group (P<0.001). Between groups, there were no statistically significant changes in mortality,non-invasive oxygen demand, or hospitalization duration. Biochemical and Clinical outcomes were comparable between those receiving hydroxychloroquine with azithromycin and those do not receive any medication.Conclusion: This treatment regimen was shown to be not affective in mild to severe positve COVID-19 hospitalized patients and was associated with a small number of mild to moderate clinical adverse effects.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22021743
- 003
- CZ-PrNML
- 005
- 20221021155249.0
- 007
- ta
- 008
- 220909s2022 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.31482/mmsl.2021.045 $2 doi
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Althanoon, Zeina A. $u College of Pharmacy, University of Mosul, Mosul, Iraq
- 245 10
- $a Evaluation of the therapeutic effects of combined hydroxychloroquine and azithromycine in patients with covid-19 / $c Zeina A. Althanoon
- 520 9_
- $a Introduction: Coronavirus pandemic is currently a global health concern with no established treatment guidelines. The aim of the present study was to determine the therapeutic effectiveness of hydroxychloroquine combined with azithromycin in patients with positive coronavirus disease 2019 (COVID-19) admitted to the hospital with severe dyspnea, as well as the incidence of occurrence of adverse effects.Methods: It was intended to utilize a retrospective clinical study of approximately 250 adult patients admitted to the ALSALAM Teaching Hospital in Mosul city with mild to moderate COVID-19 in order to evaluate treatment efficacy in combination with clinical and biochemical findings. Two groups were involved in the research. The first patient group consisted of 250 people who got hydroxychloroquine in conjunction with azithromycin, while the second untreated control group consisted of 100 individuals who received no medication as part of the research.Results: Baseline parameters (clinical and biochemical assays) did not vary substantially among the two groups. Patients in the treatment group were hospitalized at a rate of 30%, compared to 27% in the untreated control group (P<0.001). Between groups, there were no statistically significant changes in mortality,non-invasive oxygen demand, or hospitalization duration. Biochemical and Clinical outcomes were comparable between those receiving hydroxychloroquine with azithromycin and those do not receive any medication.Conclusion: This treatment regimen was shown to be not affective in mild to severe positve COVID-19 hospitalized patients and was associated with a small number of mild to moderate clinical adverse effects.
- 650 _7
- $a lidé $7 D006801 $2 czmesh
- 650 17
- $a COVID-19 $7 D000086382 $2 czmesh
- 650 _7
- $a hydroxychlorochin $x farmakologie $x terapeutické užití $7 D006886 $2 czmesh
- 650 _7
- $a azithromycin $x farmakologie $x terapeutické užití $7 D017963 $2 czmesh
- 650 _7
- $a kombinovaná farmakoterapie $7 D004359 $2 czmesh
- 650 _2
- $a farmakoterapie COVID-19 $7 D000093485
- 773 0_
- $t Vojenské zdravotnické listy $x 0372-7025 $g Roč. 91, č. 3 (2022), s. 216-223 $w MED00011116
- 856 41
- $u https://mmsl.cz/artkey/mms-202203-0006_evaluation-of-the-therapeutic-effects-of-combined-hydroxychloroquine-and-azithromycine-in-patients-with-covid-1.php $y plný text volně přístupný
- 910 __
- $a ABA008 $b A 3 $c 1073 $y p $z 0
- 990 __
- $a 20220909 $b ABA008
- 991 __
- $a 20221021155242 $b ABA008
- 999 __
- $a ok $b bmc $g 1840088 $s 1173011
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 91 $c 3 $d 216-223 $e 20220902 $i 0372-7025 $m Vojenské zdravotnické listy $x MED00011116
- LZP __
- $c NLK109 $d 20221021 $b NLK111 $a Actavia-MED00011116-20220909